<DOC>
	<DOC>NCT02910635</DOC>
	<brief_summary>The primary objective of this study is to assess the corrected QT interval (QTc) effect of volanesorsen (ISIS 304801) administered as a 300 mg subcutaneous (SC) therapeutic and a 300 mg intravenous (IV; 2-hour infusion) supra-therapeutic dose relative to placebo in healthy adult male and female subjects.</brief_summary>
	<brief_title>A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Abnormalities</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Must have given written informed consent and be able to comply with all study requirements Males and females aged 1855 at the time of informed consent Females must be nonpregnant and nonlactating surgically sterile, postmenopausal or if engaged in sexual relations of childbearing potential, using an acceptable contraceptive method Males must be surgically sterile, abstinent or using an acceptable contraceptive method The subject has a BMI of 19 to 32 kg/m^2 inclusive Consumption of nicotine or nicotinecontaining products for at least 6 months before Screening History of risk factors for Torsades de Pointes, unexplained syncope, known Long QT Syndrome, heart failure, myocardial infarction, angina, or clinical significant abnormal laboratory assessments including hypokalemia, hypocalcemia, hypercalcemia, or hypomagnesemia Abnormal screening ECG Use of concomitant medications unless authorized by the Sponsor Medical Monitor Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C or chronic hepatitis B Treatment with another Study Drug, biological agent, or device within onemonth of Screening Tests positive for drugs of abuse or cotinine Considered unsuitable for inclusion by the Principal Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Thorough QTc, Therapeutic dose, supra therapeutic dose</keyword>
</DOC>